Research Paper Volume 12, Issue 9 pp 8565—8582

Implications of maraviroc and/or rapamycin in a mouse model of fragility

Figure 2. Biochemical and metabolic parameters: AST, ALT, glucose, HOMA index, cholesterol, triglycerides. (A) A significant decrease in AST levels was recorded in all the therapeutic groups. (B) There was a decrease in ALT levels in all the therapeutic groups but only statistically significant in the MVC+RAPA group. (C) Glucose levels were discreetly superior in all the therapeutic groups, but only significant in the MVC+RAPA group. (D) Compared to control group, HOMA index was significantly higher in RAPA and MVC+RAPA group. (E) No differences were observed in the groups after analyzing the cholesterol levels. (F). Compared to control group, significantly differences were only observed after comparing it to the MVC+RAPA group. Each bar represents the mean ± SEM. *p <0.05, **p <0.01 and ***p <0.001 with respect to control. ALT, alanine aminotransferase. AST, aspartate aminotransferase. MVC, maraviroc. RAPA, rapamycin. MVC+RAPA, maraviroc plus rapamycin.